3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:百万円) |
| 前連結会計年度 (2024年7月31日) | 当連結会計年度 (2025年7月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 15,666 | 9,157 |
受取手形及び売掛金 | 4,038 | 5,038 |
電子記録債権 | 258 | 247 |
商品及び製品 | 5,292 | 6,311 |
仕掛品 | 619 | 675 |
原材料及び貯蔵品 | 806 | 864 |
その他 | 596 | 1,576 |
貸倒引当金 | △2 | △0 |
流動資産合計 | 27,275 | 23,870 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物(純額) | 2,157 | 2,082 |
機械装置及び運搬具(純額) | 725 | 708 |
工具、器具及び備品(純額) | 509 | 518 |
土地 | 1,190 | 1,194 |
リース資産(純額) | 11 | 27 |
建設仮勘定 | 16 | 164 |
有形固定資産合計 | 4,609 | 4,696 |
無形固定資産 | | |
のれん | 124 | 71 |
その他 | 52 | 49 |
無形固定資産合計 | 177 | 120 |
投資その他の資産 | | |
投資有価証券 | 3,037 | 2,450 |
繰延税金資産 | 351 | 515 |
その他 | 1,122 | 996 |
投資その他の資産合計 | 4,510 | 3,961 |
固定資産合計 | 9,298 | 8,778 |
資産合計 | 36,573 | 32,649 |
| | (単位:百万円) |
| 前連結会計年度 (2024年7月31日) | 当連結会計年度 (2025年7月31日) |
負債の部 | | |
流動負債 | | |
支払手形及び買掛金 | 1,250 | 1,923 |
短期借入金 | 14,900 | 11,400 |
1年内返済予定の長期借入金 | 760 | 560 |
未払金 | 4,039 | 3,520 |
未払法人税等 | 1,384 | 1,494 |
賞与引当金 | 72 | 72 |
その他 | 755 | 1,034 |
流動負債合計 | 23,163 | 20,005 |
固定負債 | | |
長期借入金 | 1,231 | 671 |
退職給付に係る負債 | 384 | 378 |
その他 | 208 | 45 |
固定負債合計 | 1,824 | 1,096 |
負債合計 | 24,987 | 21,101 |
純資産の部 | | |
株主資本 | | |
資本金 | 2,043 | 2,043 |
資本剰余金 | 1,814 | 1,814 |
利益剰余金 | 8,356 | 7,691 |
自己株式 | △1,194 | △195 |
株主資本合計 | 11,019 | 11,353 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 566 | 193 |
その他の包括利益累計額合計 | 566 | 193 |
純資産合計 | 11,585 | 11,547 |
負債純資産合計 | 36,573 | 32,649 |
E0248429290株式会社ファーマフーズ通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-08-012025-07-31FY2025-07-312023-08-012024-07-312024-07-311falsefalsefalse292902023-07-31jppfs_cor:CapitalStockMember292902023-07-31jppfs_cor:CapitalSurplusMember292902023-07-31jppfs_cor:RetainedEarningsMember292902023-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902023-08-012024-07-31jppfs_cor:CapitalStockMember292902023-07-31jppfs_cor:ShareholdersEquityMember292902023-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902023-08-012024-07-31jppfs_cor:CapitalSurplusMember292902023-08-012024-07-31jppfs_cor:RetainedEarningsMember292902023-08-012024-07-31jppfs_cor:ShareholdersEquityMember292902023-08-012024-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902023-08-012024-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902023-07-31292902023-08-012024-07-31292902025-09-11292902025-07-31292902024-08-012025-07-31292902024-07-31292902023-07-31jppfs_cor:TreasuryStockMember292902023-08-012024-07-31jppfs_cor:TreasuryStockMember292902023-08-012024-07-31jpcrp_cor:ReportableSegmentsMember292902025-07-31tse-acedjpfr-29290:BioMedicalReportableSegmentsMember292902024-08-012025-07-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember292902023-08-012024-07-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember292902025-07-31jpcrp_cor:ReportableSegmentsMember292902024-08-012025-07-31jpcrp_cor:ReportableSegmentsMember292902024-07-31jpcrp_cor:ReportableSegmentsMember292902023-08-012024-07-31tse-acedjpfr-29290:BtoBReportableSegmentsMember292902023-08-012024-07-31tse-acedjpfr-29290:BtoCReportableSegmentsMember292902023-08-012024-07-31tse-acedjpfr-29290:BioMedicalReportableSegmentsMember292902023-08-012024-07-31jpcrp_cor:ReconcilingItemsMember292902025-07-31tse-acedjpfr-29290:BtoBReportableSegmentsMember292902025-07-31tse-acedjpfr-29290:BtoCReportableSegmentsMember292902025-07-31jpcrp_cor:ReconcilingItemsMember292902024-08-012025-07-31tse-acedjpfr-29290:BtoBReportableSegmentsMember292902024-08-012025-07-31tse-acedjpfr-29290:BtoCReportableSegmentsMember292902024-08-012025-07-31tse-acedjpfr-29290:BioMedicalReportableSegmentsMember292902024-08-012025-07-31jpcrp_cor:ReconcilingItemsMember292902024-07-31tse-acedjpfr-29290:BtoBReportableSegmentsMember292902024-07-31tse-acedjpfr-29290:BtoCReportableSegmentsMember292902024-07-31tse-acedjpfr-29290:BioMedicalReportableSegmentsMember292902024-07-31jpcrp_cor:ReconcilingItemsMember292902023-08-012024-07-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember292902024-08-012025-07-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember292902024-08-012025-07-31jppfs_cor:CapitalStockMember292902024-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902024-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902024-07-31jppfs_cor:ShareholdersEquityMember292902024-07-31jppfs_cor:TreasuryStockMember292902024-07-31jppfs_cor:RetainedEarningsMember292902024-07-31jppfs_cor:CapitalSurplusMember292902024-07-31jppfs_cor:CapitalStockMember292902025-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902025-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902025-07-31jppfs_cor:ShareholdersEquityMember292902025-07-31jppfs_cor:TreasuryStockMember292902025-07-31jppfs_cor:RetainedEarningsMember292902025-07-31jppfs_cor:CapitalSurplusMember292902025-07-31jppfs_cor:CapitalStockMember292902024-08-012025-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902024-08-012025-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902024-08-012025-07-31jppfs_cor:ShareholdersEquityMember292902024-08-012025-07-31jppfs_cor:TreasuryStockMember292902024-08-012025-07-31jppfs_cor:RetainedEarningsMember292902024-08-012025-07-31jppfs_cor:CapitalSurplusMemberiso4217:JPYxbrli:pure